The effect of Rosvastatin on steatosis and fibrosis in patients with non-alcoholic fatty liver disease

The effect of Rosvastatin on steatosis and fibrosis in patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017060212789N14

Enrollment

Registered

2017-06-12

Start date

2017-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease (NAFLD). Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Control Group: patients received placebo daily plus standard treatment for fatty liver disease. Intervention 2: Intervention Group: patients received 10 mg Rosvastatin daily plus stand

Treatment - Drugs

Control Group: patients received placebo daily plus standard treatment for fatty liver disease.

Intervention Group: patients received 10 mg Rosvastatin daily plus standard treatment for fatty liver disease.

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Main Inclusion Criteria: Non diabetics patients; normal FBS; BS2hpp;Hb1AC; Age 20 years and older; approved non fatty liver diagnosed by fibroscan; LFT(AST and ALT); rejection of other causes of fatty liver disease such as hepatitis B and C . Main Exclusion Criteria: Patients who have other liver diseases; contraindication for Rosvastatin; not taking hypoglycemic drugs such as metformin.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Steatosis of liver. Timepoint: Before intervention, six month after intervention. Method of measurement: Fibroscan.;Fibrosis of liver. Timepoint: Before intervention, six month after intervention. Method of measurement: Fibroscan.	—

Secondary

Measure	Time frame
ALT. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;AST. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;LDL. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;HDL. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Triglyceride. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Bilirubin. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Blood urea. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Blood creatinine. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.	—

Measure

Time frame

ALT. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;AST. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;LDL. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;HDL. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Triglyceride. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Bilirubin. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Blood urea. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Blood creatinine. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Nematollah Naghshbandi

Kurdistan University of Medical Sciences

dr.n.naghshbandi@gmail.com+98 87 3328 6112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026